F
laviviruses are associated with a number of mosquito-transmitted diseases worldwide and are serologically divided into several complexes, including medically important members of the Japanese encephalitis virus (JEV), dengue virus (DENV), and yellow fever virus (YFV) serocomplexes (1) . The DENV serocomplex, comprised of four antigenically distinct serotypes (DENV-1 to -4), is the most important and rapidly emerging group of arthropod-borne pathogens, imposing a great economic and public health burden, especially in tropical and subtropical countries (2) (3) (4) (5) . A recent study estimates that 390 million DENV infections occur worldwide annually, with 500,000 severe cases and 25,000 deaths, mostly affecting children (6) . Currently, there is no DENV vaccine available. The most advanced dengue vaccine in development is the tetravalent chimeric YF-17D dengue (TCYD) vaccine. Currently, the TCYD vaccine is in a large-scale human efficacy trial, and the vaccine has been estimated to achieve 56% efficacy based on the primary endpoint calculation (7) . Optimistically, the TCYD vaccine could be available globally in the very near future. Thus, a serological assay that can differentiate natural infection from vaccination, and be used as a surveillance tool to monitor vaccine effectiveness, is urgently needed.
Conventional serological tests such as neutralization (Nt), hemagglutination inhibition (HAI), and IgM and IgG antibodycapture enzyme-linked immunosorbent assays (MAC-and GACELISAs, respectively), which exclusively measure antibodies to the premembrane (prM) and envelope (E) structural proteins of flaviviruses, cannot be used to determine natural infections among vaccinated populations (8) . Antibodies to nonstructural protein 1 (NS1) have been proposed as serological markers of natural infection among inactivated Japanese encephalitis virus (JEV)-vaccinated populations, and an NS1-ELISA has been developed (9) (10) (11) . However, this NS1-ELISA required that either the microplates be sensitized with purified NS1 or NS1 antigen be captured by NS1-specific murine monoclonal antibodies, before adding test human serum specimens. We speculate that the sensitivity of NS1-specific IgM or IgG isotyping might be reduced due to the competition between two antibody isotypes for the same antigenic sites. Isotype-specific antibody-capture ELISA eliminates the isotype competition for the same antigenic sites and, thus, enhances the sensitivity of the assay. A number of commercially available anti-prM/E ELISA kits for both IgM and IgG detection are commonly used for DENV clinical serodiagnosis, and results from comprehensive evaluations suggest a good correlation of these assays with the gold standard Nt test (12) (13) (14) .
Our long-term goal is to develop anti-NS1 MAC-and GACELISAs that can be used as tools to differentiate the immune responses elicited by vaccinations from those elicited by natural infections. We initiated this study to develop and optimize the NS1-MAC-and GAC-ELISAs using recombinant NS1 antigens. Using an archived flavivirus-infected clinical serum panel, the objectives of this initial study are (i) to determine the sensitivity and specificity of the NS1-MAC/GAC-ELISA compared to the standard E-MAC/GAC-ELISAs and (ii) to determine the cross-reactivity of NS1-MAC/GAC-ELISA between different serocomplexes of flaviviruses. We hypothesize that lower sensitivities of NS1 antibody detection, as reported in previous studies (9, 11) , are due to a relative abundance of anti-prM/E antibodies in the serum of infected individuals. In this study, we propose that a procedure to deplete anti-prM/E antibodies using prM/E-containing virus-like particles (VLPs) can improve the sensitivity of NS1-ELISA. Furthermore, panels of DENV-infected serum pairs collected during the acute and convalescent phases were used for extensive comparison of the correlation and agreement of the assays by testing simultaneously with NS1-and VLP-MAC/GAC-ELISAs and InBios DENV Detect IgM capture ELISA. The test algorithm was expanded to the single serum collection panel for the test validation by calculating the sensitivity and specificity of the assay performance since a single-time-point clinical sample is the most common practice in the field study.
MATERIALS AND METHODS
Cell culture, plasmid construction, and soluble protein expression. COS-1 cells (ATCC CRL 1650; Manassas, VA) were grown at 37°C with 5% CO 2 in Dulbecco's modified Eagle's minimal essential medium (DMEM; Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone Laboratories, Inc., Logan, UT), 110 mg/liter sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 20 ml/liter 7.5% NaHCO 3 , 100 U/ml penicillin, and 100 g/ml streptomycin. A transcriptionally and translationally optimized eukaryotic cell expression plasmid was used as the backbone to express premembrane/envelope (prM/E) or NS1 protein of six medically important flaviviruses, including DENV-1 strain 16007, DENV-2 strain 16681, DENV-3 strain C0331/94, DENV-4 strain H241, West Nile virus (WNV) strain NY99, and Japanese encephalitis virus (JEV) strain SA14-14-2 for prM/E and strain CH1392 for NS1. Molecular cloning procedures to construct these plasmids were described previously (15, 16) . The VLPs and soluble NS1 protein (sNS1) were expressed by COS-1 cells electroporated with recombinant expression plasmids containing the prM/E and NS1 genes, respectively, using the protocol described previously (17, 18) . Electroporated cells were recovered in 50 ml DMEM, seeded into three separate 75-cm 2 culture flasks for VLP/sNS1 expression, and incubated at 28°C with 5% CO 2 . The secretion of recombinant antigens was determined from tissue culture medium harvested 4 to 5 days posttransformation for VLP and sNS1, respectively.
Antigen titration and VLP-and NS1-specific MAC/GAC-ELISAs. Antigen-capture ELISAs (Ag-ELISAs) were used to detect and quantify secreted antigens from the prM/E and NS1 gene-carrying-plasmid-transformed COS-1 cells as described previously (17, 18) . Anti-DENV-1 to -4, WNV, or JEV VLP and NS1 polyclonal rabbit sera were used to capture the antigens. Murine hyperimmune ascetic fluid (MHIAF) specific for DENV-1 to -4, WNV, or JEV was diluted 1:2,000 for detection. Both the polyclonal capture and detector sera containing high-titer immunoglobulin recognizing all potential antigenic epitopes were generated at the Centers for Disease Control and Prevention, Atlanta, GA, USA (CDC). Antigen concentrations were standardized at an optical density at 450 nm (OD 450 ) of 1.4, within the region of antigen excess near the upper asymptote of the sigmoidal antigen dilution curve, because antigens are considered to be the limiting factor relative to the high concentration of polyclonal rabbit serum and MHIAF antibodies used for capture and detection, respectively.
Human sera were assayed for the presence of prM/E-and sNS1-specific antibodies using both MAC-and GAC-ELISAs as previously described (18) . Briefly, 96-well plates were coated with goat anti-human IgM or IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) that was diluted 1:2,000 in phosphate-buffered saline (PBS) buffer and incubated overnight at 4°C. DENV-, WNV-, or JEV-infected patient sera and positive-and negative-control sera were diluted 1:2,000 in wash buffer (PBS with 0.05% Tween 20), added to wells, and incubated at 37°C for 120 min. DENV, WNV, or JEV VLPs and sNS1 were diluted appropriately in wash buffer and tested against each serum sample in triplicate. MHIAFs against homologous antigens were used as detectors. The mock-transfected cell culture supernatants or 5% milk-PBS was used as a negative antigen control for the standard quantification titration curve and for the MAC/GAC-ELISA, respectively. The positive-to-negative ratio (P/N) values were determined according to the procedure described previously (18) using internal positive and negative serum controls included in each 96-well plate. Positive (P) values for each specimen were determined as the average OD 450 for the patient serum sample reacted with positive viral antigen. Negative (N) values were determined for individual 96-well plates as the average OD 450 for the normal human serum control reacted with the positive viral antigen. This P/N ratio is the current standard used in the diagnostic lab in CDC to interpret test results.
To deplete anti-prM/E antibodies, the same procedure as described for the Ag-ELISA was used to capture secreted VLP antigens over the 96-well plates. The patients' or negative-control sera were diluted 1:2,000 in PBS as previously suggested (19) , premixed with VLP antigens, added immediately to wells, and incubated at 37°C for 60 min. A total of 50 l of prM/E antibody-depleted sera was transferred to the precoated anti-human IgM or IgG plates for MAC/GAC-ELISA as described above.
Human serum panel. Archived serum specimens were obtained from the Arboviral Diseases Branch, Division of Vector-Borne Diseases, CDC. Clinical diagnostic serum specimens available from 1999 to 2008 were assembled, and the status of infection was confirmed by 90% focus-reduction microneutralization test (FRNT 90 ). This archived serum panel included 54 acute-and convalescent-phase presumptive DENV-infected patient serum pairs from Brazil and 97 presumptive WNV-infected patient serum specimens from South Dakota. Thirty non-DENV patient serum specimens were assembled as a control panel, including IgG-positive yellow fever-17D (YF-17D) postvaccinated sera (n ϭ 10) and acutephase patient serum specimens from St. Louis encephalitis virus (SLEV) (n ϭ 2), Zika virus (n ϭ 1), Chikungunya virus (n ϭ 10), and other viral (n ϭ 7) infections. Thirty-six normal human sera from the CDC blood bank were included as the naive serum control. Among 54 paired serum specimens from Brazil, 36 pairs showed a 4-fold increase of Nt antibodies by FRNT 90 and were further classified as taken from individuals with recent DENV infections. Seventy-four travel-related, suspected DENVinfected patient sera, collected from October 2008 to February 2009, originally sent to ARUP Laboratories (Salt Lake City, UT) and obtained through InBios (Seattle, Washington), were used as a testing panel for validation of the assay. The serum panels with evidence of JEV (n ϭ 16) infection were assembled from Taiwanese residents and provided by the Center for Disease Control in Taiwan (Taiwan-CDC), and the JEV infection status was determined by VLP-MAC-and GAC-ELISA. An institutional review board (IRB) waiver to use this serum panel was approved by the CDC human studies review board.
Statistical analysis. Student's t test for comparisons between normally distributed continuous variables and the Mann-Whitney U test for comparisons between continuous variables that are not normally distributed were used. The Pearson correlation of coefficient represented the linear relationship between the P/N (OD 450 of test specimen divided by OD 450 of negative-control specimen) ratios obtained from two methods of VLP and NS1-MAC-ELISA or VLP and NS1-GAC-ELISA. Its value ranges from Ϫ1 to ϩ1, with 1 representing the perfect correlation of the two methods. A significance level ␣ of 0.05 was obtained under the two-tailed P value. A P value of Ͻ0.05 rejected the null hypothesis that there exists no correlation between VLP and NS1 methods. Bland-Altman analysis was used to measure the agreement of P/N values between anti-VLP and anti-NS1 MAC-or GAC-ELISA. The Bland-Altman plot was obtained by plotting the difference of the two methods' P/N ratio values (P/N ratio of VLP-MAC/GAC-ELISA minus P/N ratio of NS1-MAC/GAC-ELISA) with the average from the two methods. It generated a bias value, which indicated a systematic difference between two methods and was calculated by taking the mean difference of the P/N value. The limits of agreement were calculated as 1.96 ϫ standard deviation (SD) of the difference.
The positive likelihood ratio (LRϩ), which was used to determine the optimal cutoff value of P/N ratio from MAC/GAC-ELISA, was calculated by dividing sensitivity by 100 Ϫ specificity to indicate the predicted probability of the infection based on the different cutoff levels. The LR indicates the ratio value between the probability of a given test result among people with confirmed infection and the probability of that test result among people without the infection. Thus, the positive likelihood ratio (LRϩ) indicates that a given test performed on people with confirmed infection favors positive results under the chosen cutoff value. The magnitude of the LR provides intuitive meaning as to how strongly a given test result can be used to predict the likelihood of the evidence of infection or noninfection. The comparative receiver operating characteristic (ROC) curve analysis was used to compare the paired-assay performance, and the accuracy of discrimination was measured by the area under the ROC curve (AUC). A test with perfect discriminatory power (100% sensitivity and 100% specificity) has a ROC plot that passes through the upper left corner. Therefore, the higher that the value of the AUC is, the higher that the overall accuracy of the test is. The AUC and 95% confidence interval (95% CI) were calculated by a parametric method using a maximum likelihood estimator. An AUC approaching 1 indicates that the test is highly sensitive as well as highly specific; an AUC approaching 0.5 indicates that the test is neither sensitive nor specific. For all statistical analyses, we used GraphPad Prism version 6, and P values less than 0.05 were considered statistically significant.
RESULTS
Detection of DENV anti-NS1 antibodies by MAC/GAC-ELISA before and after depletion of anti-prM/E antibodies. Previous studies reported that the lower sensitivity of detecting anti-NS1
FIG 1
Analysis of the effect of depletion of anti-prM/E antibodies on NS1-MAC/GAC-ELISA using four different serotypes of antigens individually or in combination on three human sera confirmed as primary DENV-1 and DENV-2 and secondary DENV-2 infection, respectively. (A and B) P/N ratio values of IgM (A) and IgG (B) using a single serotype of VLPs for depletion and the same serotype of NS1 antigens for NS1-MAC-ELISA (both indicated on the x axis) using primary DENV-1 (left panel), primary DENV-2 (middle panel), and secondary DENV-2 (right panel) infection. (C) P/N ratio values of IgM and IgG using a combination of serotype 2 and 3 VLPs for depletion and the same combination of serotypes (2 and 3) of NS1 antigens for NS1-MAC-ELISA. P/N ratio without depletion of anti-E antibodies is shown by white bars, and that after depletion is shown by hatched bars. Normal human serum was used as a negative control to calculate the P/N ratio value by dividing the OD 450 of DENV-confirmed patient serum by that of negative-control serum. All data were obtained from three independent experiments, and standard deviations are indicated.
antibodies than of anti-prM/E antibodies after flavivirus infection (9, 11) may be due to the competition of a relative abundance of anti-prM/E antibodies compared to anti-NS1 antibodies in serum specimens. Preabsorption of serum with VLPs to deplete abundant anti-prM/E antibodies could improve the performance of NS1-MAC/GAC ELISAs. Due to the limited volume of available sera and the complexity of assay optimization, three DENV-confirmed human serum specimens were used to compare the P/N ratios of NS1-MAC/GAC-ELISAs, before and after depletion of anti-prM/E antibodies. These samples were also used to determine the combinations of VLPs and NS1 used for prM/E antibody depletion and NS1 antibody detection. First, a single serotype of VLP was used for depletion and the same sNS1 serotype antigen was used for NS1-MAC/GAC-ELISAs. Serum preabsorbed with VLPs to deplete anti-prM/E antibodies increased the P/N ratio for anti-NS1 IgM and IgG-capture ELISA, as shown in Fig. 1A and B, respectively. Interestingly, the homologous sNS1 used in NS1-MAC/GAC-ELISAs for the postdepletion serum did not always give the highest P/N ratio. Our results suggest that anti-prM/E and anti-NS1 antibodies are highly cross-reactive to other DENV serotypes after DENV infection. Furthermore, depletion of antiprM/E antibodies enhances anti-NS1 IgM and IgG antibody detection.
Different serotype combinations of VLP antigens, including double, triple, and quadruple antigens, were further tested for depletion, and the same combinations of sNS1 antigens were used for detection in NS1-MAC/GAC-ELISA. The results suggest that using dual-serotype VLPs for depletion is sufficient to detect anti-NS1 antibodies, although slightly lower values of P/N ratios were found compared to those using homologous single VLPs and sNS1 for depletion and detection, respectively ( Table 1) .
The recently FDA-approved InBios DENV Detect IgM capture ELISA kit (InBios International, Inc., Seattle, WA) uses a combination of DENV-2 and DENV-3 VLPs for detection. In order to consistently compare the MAC/GAC-ELISA results between antiprM/E and anti-NS1 antibodies, DENV-2 and DENV-3 VLPs were used for depletion and the same DENV-2 and -3 combination of NS1 was used for NS1-MAC/GAC-ELISAs. The results suggest that the significant increase of P/N ratios was found for all three serum samples taken from DENV-infected individuals (Fig.  1C) . Thus, the combination of DENV-2 and -3 VLPs and sNS1 was used for the remaining assays.
Comparison between VLP-and NS1-MAC/GAC-ELISAs from acute-and convalescent-phase DENV sera. Since the appearance of IgM/IgG in human sera varies depending on the time of collection and the status of past exposure, 36 DENV-infected serum pairs collected during the acute and convalescent phases, with evidence of 4-fold increases of FRNT 90 titers, were used for extensive comparison by testing simultaneously with NS1-and VLP-MAC/GAC-ELISAs and InBios DENV Detect IgM capture ELISA. NS1-MAC/GAC-ELISAs showed significant increases of P/N ratio values after depletion among both acute-and convalescent-phase sera ( Fig. 2A and B) . Extensive comparisons among all three ELISA methods showed high degrees of correlation among either acute-or convalescent-phase sera with statistical significance (P Ͻ 0.05) (Fig. 2C and D) . Although an inverse correlation of IgG from the convalescent-phase sera between the VLP-GACand NS1-GAC-ELISAs was observed, nearly all 36 DENV-con- firmed serum specimens (except one sample) showed high P/N ratio values by NS1-GAC-ELISA but variable values by VLP-GAC-ELISA (Fig. 2C, bottom right panel) . Bland-Altman analyses also showed good agreement between the two VLP-and NS1-MAC/GAC-ELISA methods over the entire P/N ratio range for DENV-confirmed specimens. Negative bias values were observed in acute-phase sera, but positive bias values were observed in convalescent-phase sera ( Fig. 2E and F) . Sensitivity and specificity of NS1-MAC/GAC-ELISA. The magnitude of LRϩ, the ratio of sensitivity over 100 Ϫ specificity, provides information on how strongly a given test result can be used to predict the likelihood of evidence of infection or noninfection based on P/N values from 54 presumptive DENV patient sera and the 66-sample control serum panel (Fig. 3A) . The optimal cutoff values of P/N ratio for both NS1-MAC-and -GAC-ELISAs of acute-phase sera fell at 0.99 and 1.31, respectively, and both fell at 1.31 for convalescent-phase sera (Fig. 3B and C) . Based on the cutoff, higher sensitivity but lower specificity of NS1-MAC-ELISA was observed from the acute-phase sera than from the convalescent-phase sera; however, similar sensitivity and specificity of NS1-GAC-ELISA were observed from both the acute-and convalescent-phase sera.
Upon detailed analysis of the 54 presumptive DENV patient paired sera, 36 showed 4-fold increases in FRNT 90 titers and were classified as current infections and the remaining 18 sera were judged as resulting from previous exposures (see Table S1 in the supplemental material). Further excluding those 18 sera with past exposure, the sensitivity of NS1-MAC-ELISA reached 88.9% (32/36) for acute-and 97.2% (35/36) for convalescent-phase sera.
Comparison of the performance between VLP-and NS1-MAC/GAC-ELISAs. The performance of MAC/GAC-ELISAs was evaluated by calculating the AUC between VLP-and NS1-MAC/ GAC-ELISAs using the travel-associated acute DENV-infected serum panel for validation. The results showed comparable performance with no statistical significance ( Table 2) .
We further expanded this method to detect anti-NS1 IgM and Table 2) . Specificity of NS1-MAC-ELISA between different serocomplexes of flavivirus. To further evaluate if NS1 antibodies from DENV infection are cross-reactive with those from other serocomplexes of flavivirus infection, 10 WNV patient serum specimens and 10 YF-17D-vaccinee serum specimens were tested using the combination of DENV-2 and -3 VLPs and sNS1 antigens for absorption and detection, respectively, as described above. Figure 4A shows the results of WNV patient sera with the P/N ratio values below 2 for DENV NS1-MAC/GAC-ELISA, although those of WNV NS1-MAC/GAC-ELISA are significantly high, particularly those of WNV NS1-MAC-ELISA. Figure 4B (right panel) shows a P/N of Ͻ2 of 10 YF-17D-vaccinee sera for GAC-ELISA using WNV-NS1 antigens. Only one specimen among the 10 YF-17D-vaccinee sera showed anti-NS1 IgG antibodies to DENV NS1. Furthermore, three among them show cross-reactive anti-NS1 IgM antibodies to WNV NS1 (P/N of Ͼ2) but not to DENV NS1 (Fig. 4B,  left panel) .
DISCUSSION
Laboratory assays designed to detect flavivirus-specific IgM have proven to be very useful for the diagnosis of DENV, JEV, and
Optimal cutoff P/N value, sensitivity, and specificity of NS1-MAC/GAC-ELISAs. Optimal cutoff value was determined by the magnitude of positive likelihood ratio (LRϩ) calculated by dividing sensitivity by 100 Ϫ specificity. (A) Example plot of sensitivity versus 100 Ϫ specificity of both MAC-ELISA (left panel) and GAC-ELISA (right panel) based on P/N ratio values from 54 DENV-confirmed convalescent-phase sera and 66 control sera. (B and C) Sensitivity and specificity of NS1-MAC-ELISA (left panels) and NS1-GAC-ELISA (right panels) based on the optimal cutoff P/N value obtained from 54 DENV-confirmed acute-phase (B) and convalescent-phase (C) sera and 66 control sera.
WNV infections (12, 13, 18, 20) . However, those assays are based on detecting anti-prM/E antibodies. The NS1 protein is the only nonstructural protein secreted from infected mammalian cells and infected patients' sera among the seven nonstructural proteins of flaviviruses, and its crystal structure has recently been resolved (21) (22) (23) (24) . NS1 is a potent immunogen, and anti-NS1 antibodies are partially protective against virus challenge in laboratory animal studies (25) (26) (27) (28) . Thus, the levels of anti-NS1 antibodies are expected to be higher than those of antibodies against the other nonstructural proteins. Although significant progress has been made to improve the diagnostic methods for the detection of antibodies against flavivirus NS1, including a previously pub- a Same protocol as DENV NS1-ELISA of using JEV-or WNV-VLP for depletion of prM/E antibodies and JEV-or WNV-NS1 for NS1-MAC/GAC-ELISA. b Control panels were other serocomplex panels and negative panels. lished indirect ELISA, an epitope-blocking ELISA, or a complement-dependent cytotoxicity assay (29) (30) (31) (32) , the use of an NS1-MAC-ELISA has not been reported, and validated test kits
are not yet commercially available. Our current study successfully developed a novel approach to deplete anti-prM/E antibodies and demonstrated the sensitivity and specificity of NS1-MAC/GACELISAs for anti-NS1 antibody detection. The extensive comparison by testing both acute-and convalescent-phase DENV-infected sera simultaneously with NS1-and VLP-MAC/GAC-ELISAs and InBios DENV Detect IgM capture ELISA showed a high degree of correlation and agreement, except for an inverse correlation of the convalescent-phase sera between the VLP-and NS1-GAC-ELISAs. However, 35 out of 36 DENV-confirmed serum specimens showed high P/N ratio values (Ն5) by NS1-GAC-ELISA but variable values (range, 1.27 to 16.92) by VLP-GAC-ELISA. Although the mechanism behind this is currently unknown, the diagnostic performances between antiprM/E and NS1 detections were similar. Previous studies report that anti-NS1 antibodies are present in low levels in serum after flavivirus infection, hence, its poor detection (10, 31) . This might be due to a relative abundance of anti-prM/E antibodies, which results in lower sensitivity of NS1 isotype assays. Indeed, the P/N ratio value of NS1-MAC-ELISA significantly increased after the depletion of anti-E/M antibodies. When the depletion of NS1 antibodies was performed on sera before performing VLP-MAC-ELISA, we did not observe any significant difference in OD readings before and after the depletion of NS1 antibodies (data not shown). This observation supports the idea that anti-NS1 IgM antibodies are in the minority population compared to anti-VLP IgM antibodies in acute dengue serum specimens, and the anti-NS1 IgM antibodies do not have a sufficiently high titer to compete with anti-VLP IgM antibodies in the IgM-capture step. Based on the increase in P/N ratio value, the concentrations of antiprM/E antibodies were presumably 3-to 12-fold higher than those of anti-NS1 antibodies in the human serum depending on the timing of serum collection (date not shown). Furthermore, previous studies suggest that NS1 ELISAs can be used not only to differentiate natural infections from JEV vaccinations but also to differentiate primary and secondary dengue virus infections, with a serotyping capability (33, 34) . In the current study, we demonstrate that NS1 antibodies, regardless of isotype, are highly cross-reactive within the DENV serocomplex ( Fig. 1) but poorly cross-reactive between DENV and the YFV/ WNV serocomplex (Fig. 4) . The only specimen among YF-17D-vaccinee sera which showed cross-reactive anti-NS1 IgG antibodies to DENV NS1 was probably due to previous exposure to DENV. The advantages of using the anti-NS1 IgM/IgG capture method developed in this study include (i) the avoidance of isotype competition for the same antigenic sites, as previously published (35); (ii) the use of small quantities of serum; (iii) higher serocomplex specificity, as shown in Fig. 4 ; and (iv) comparable sensitivity (89.2%; 95% CI, 79.8 to 95.2) of NS1-MAC-ELISA to that of VLP-MAC-ELISA (96%; 95% CI, 88.6 to 99.2) or InBios DENV Detect IgM capture ELISA (80.8%; 95% CI, 69.6 to 88.8). Although VLP-MAC-ELISA and InBios DENV Detect IgM capture ELISA detected anti-prM/E antibodies, the different sensitivities of the two assays could be due to the determination of the cutoff value used in each assay. In-house VLP-MAC-ELISA calculates the cutoff value by dividing the OD values from the testing serum and the negative serum control using VLPs as the antigens (18) . The InBios DENV Detect IgM capture ELISA determines the immune status ratio (IMR) by dividing the OD value of the testing serum using VLPs with the OD value of testing serum using negative antigens (as shown in the product insert of the InBios kit). It has been anticipated that the TCYD vaccine will soon be approved by regulatory agents and introduced to the global market in the next few years (7) . The NS1s of TCYD vaccine are derived from YF-17D. Our NS1-MAC/GAC-ELISA could have a great potential to be used as a unique serosurveillance tool to distinguish natural infection from vaccination and to monitor vaccine effectiveness.
NS1 antibodies have been long recognized as complement fixation antibodies, which stimulate complement pathway for antigen clearance (1, 36) . Compared to the long duration of anti-prM/E antibodies in the postinfection human sera, the duration of anti-NS1 antibodies of DENV in serum samples was unknown, although previous studies suggested that they could last for up to 4.2 years in JEV-infected cases (9) . Eighteen specimens in our Brazilian collection were classified as previous DENV exposures with no evidence of 4-fold increase of FRuNT 90 titer. None of these specimens were positive by NS1-MAC-ELISA (P/N, Յ1.98), and only one specimen was positive by NS1-GAC-ELISA (P/N, Յ3.79), when the cutoff value was chosen to yield 100% specificity. Seventeen out of 18 specimens had FRuNT 90 titers of at least 1:10 against at least one DENV serotype in the acute-phase serum collection (see Table S1 in the supplemental material). The persistence of NS1-IgM and -IgG antibodies is unknown after DENV infection. Our data suggest the short duration of DENV NS1 antibodies and the potential utility of NS1-MAC and/or GAC-ELISA for community-based seroepidemiological studies.
The major limitation of this study is the lack of access to the vaccinee sera from the dengue vaccine clinical trial (the investigators signed the contract with the commercial company), and therefore, an archived clinical serum panel was used instead, with limited numbers as well as limited demographic data and status of collection information. To overcome this limitation, we are collaborating with laboratories in areas where dengue is endemic to expand our study and to include (i) reverse transcriptase PCR and/or NS1 antigen-confirmed acute DENV patient serum to increase the number of clinical specimens and (ii) multiple, sequentially collected DENV patient sera to determine the duration and persistence of anti-NS1 IgM and/or IgG antibodies. However, the usefulness of NS1-ELISAs to distinguish antibodies elicited by TCYD vaccine or natural infection, and to estimate the efficacy of this vaccine, may not be known until its official introduction to the community.
